Business, energy, technology, markets and global industry news from Business News Today

AI drug discovery

PharmaDeviceNews AI drug discovery
Representative image depicting advanced drug discovery targeting transcription factors and protein–protein interactions, aligned with the article exploring how AI and structural chemistry platforms like those from PRISM BioLab and Talus Bioscience are redefining intracellular drug development.
Features & Analysis

Can AI and chemistry finally converge to drug transcription factors? The race to target the cell’s command center

For decades, pharmaceutical pipelines have danced around one of biology’s most powerful but untouchable entities: transcription factors. These master regulators control gene expression and orchestrate cellular behavior, yet their structure and function have kept them out of reach for small molecule therapeutics. Unlike enzymes or receptors, transcription factors operate deep within the cell nucleus, often

Read More
Representative image of transcription factor and protein–protein interaction drug discovery, reflecting PRISM BioLab and Talus Bio’s AI-powered strategy to target undruggable intracellular pathways.
Pharma & Biotech

Can PRISM BioLab and Talus Bio finally drug the undruggable with AI and PPI chemistry?

PRISM BioLab and Talus Bio aim to drug the undruggable with AI–PPI chemistry. Find out how this platform could transform transcription factor drug discovery.

Read More
Pharma & Biotech

How the Brii–OpenBench deal could redefine early-stage drug discovery economics

Brii Biosciences Limited and OpenBench, Inc. have announced a strategic collaboration to integrate OpenBench’s structure-based artificial intelligence platform into Brii Biosciences’ discovery efforts. The partnership grants Brii Biosciences exclusive rights to novel lead compounds identified through OpenBench’s proprietary screening technology. The agreement includes an option to expand into additional programs, underscoring Brii Biosciences’ push into

Read More
Pharma & Biotech

Inside Insilico Medicine’s CKD push: AI-driven ISM4808 heads to Greater China with TaiGen

Insilico Medicine has licensed its AI-discovered oral PHD inhibitor ISM4808 to TaiGen Biotechnology for exclusive development and commercialization in the Greater China region, including Mainland China, Hong Kong, Macau, and Taiwan. The deal follows Investigational New Drug clearance in China in 2023 and positions TaiGen to bring the asset into clinical trials targeting anemia associated

Read More